Understanding CGRP in Migraine Therapy KundlasMD
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
CGRP Migraine Medication Revolution (2026): Prevention, Abortive Options & Avoiding Medication Overuse Dr. Kulmeet Kundlas explains that migraine is a neurological event affecting 1.2 billion people and often leads to pain, disability, and medication overuse headache when treated repeatedly with NSAIDs, triptans, or opioids. He describes migraine biology involving the trigeminal nerve and CGRP release causing blood vessel dilation, brain sensitization, and inflammation, along with four migraine stages and the lack of a definitive diagnostic test. Treatment should include prevention and abortive strategies, emphasizing CGRP-targeted therapies: monoclonal antibodies that neutralize CGRP for prevention (monthly, quarterly, or IV options, including use from age six and up) and oral CGRP receptor antagonists (gepants like Ubrelvy and Nurtec) for acute attacks, which are not shown to cause medication overuse headache. He recommends tracking attacks with a migraine diary, aims for a 50% reduction in frequency/severity/duration, notes evolving guidelines and insurance support for CGRP drugs as first-line therapy, and highlights preventing progression to chronic migraine, especially when attacks exceed four.